Performance in Initiating - Q4: 2017/2018 (1st April 2017 - 31st March 2018)

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Site Invited	Site Selected	HRA Approval	Site Confirmed by Sponsor	Site Confirmed	Non Confirmation Status	Site Ready to Start	First Patient Recruited	Reasons for delay
17/LO/0035	218519	Actif - Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis. A randomised controlled trial and parallel process evaluation	06/01/2016	26/06/2017	17/05/2017	31/08/2017	01/09/2017	NA	15/09/2017	12/10/2017	Sponsor. Document pack sent early in order to sign the contract so the CQUIN payment could be released. Study schedule meant recruitment could not start until September 2017. 40 day metric also not met due to same reasons.
17/SC/0014	219973	OPEN WATER - OPEN WATER, Global Post-Market Registry using Waterjet Ablation Therapy for Endoscopic Resection of prostate	07/12/2016	27/07/2017	13/04/2017	17/08/2017	22/08/2017	NA	23/08/2017	31/08/2017	None
17/WM/0106	201079	MOTILITY: Small bowel motility quantified by cine MRI as a predictor of long term response in patients with Crohn's disease commencing biological therapy	05/09/2017	05/09/2017	28/04/2017	29/09/2017	31/10/2017	NA	31/10/2017	25/01/2018	Neither - patients screened but none eligible. 40 day metric not met due to Sponsor delays with contract.
17/SC/0034	217773	ARK - Antibiotic Reduction and Conservation in Hospitals	28/07/2017	09/10/2017	21/03/2017	07/11/2017	14/11/2017	NA	15/11/2017		Neither - protocol design means that patients will not be consented until later on in the study.
16/LO/2195	219516	TRITON 2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	19/04/2017	18/07/2017	28/03/2017	30/08/2017	04/09/2017	NA	04/09/2017	20/09/2017	40 day metric not achieved due to Sponsor taking 3 weeks to respond to budget negotiations

17/EM/0120	222298	TRITON 3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	19/04/2017	11/07/2017	30/06/2017	30/08/2017	04/09/2017	NA	04/09/2017	04/10/2017	Neither - Protocol design means timings would not adhere to the 70 day metric. 40 day metric not achieved due to Sponsor taking 3 weeks to respond to budget negotiations
17/NI/0124	227551	EMERALD: Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy	04/08/2017	11/10/2017	10/10/2017	16/11/2017	21/11/2017	NA	30/11/2017	18/12/2017	None
17/LO/1802	199038	EQUIPTT - Evaluation of QUIPP app for Triage and Transfer	12/07/2017	14/12/2017	23/11/2017	09/01/2018	11/01/2018	NA	12/02/2018		Neither - protocol design means that patients will not be consented until later on in the study.
16/EE/0305	190307	PRIMETIME - Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers	31/03/2016	20/10/2017	03/11/2016	17/01/2018	10/01/2018	NA	31/01/2018	28/02/2018	NHS provider - Delays with setting up cross site and PI availability plus pathology engagement
17/NS/0018	223787	FUTURE: Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms	13/12/2017	12/01/2018	11/08/2017	16/02/2018	19/02/2018	NA	05/03/2018	21/03/2018	None
17/NE/0331	229957	ANACONDA: A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda device	08/08/2017	23/01/2018	20/12/2017	09/02/2018	12/02/2018	NA	21/02/2018	21/03/2018	None
17/SW/0273	235783	Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and LucentisÂ® in Subjects with Neovascular Age-related Macular Degeneration	28/11/2017	26/01/2018	22/01/2018	12/03/2018	20/03/2018				Sponsor: 40 day metric not achieved due to Sponsor delays in budget negotiations

18/EM/0027	235145	A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)	16/01/2018	16/01/2018	28/02/2018	29/03/2018					Sponsor: 40 day metric not achieved due to Sponsor delays in budget negotiations
18/LO/0133	228164	MIAMI: Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility study	20/02/2018	28/03/2018	15/03/2018						FP & WP.
17/WA/0383	233958	WHITE 5: A randomised controlled trial comparing contemporary uncemented hemiarthroplasty with standard-of-care cemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures	09/02/2018	09/02/2018	31/01/2018	14/03/2018	15/03/2018				
17/WA/0242	228068	PULSAR: Prostatic Urethral Lift in Subjects with Acute Urinary Retention Study	17/05/2017	21/03/2018	01/08/2017						